Advanced Enzymes has completed the acquisition of a controlling stake in SciTech Specialities.

Share Market Live

NSE

On synergies of this acquisition, Mukund Kabra, whole-time director of Advanced Enzymes said, “The objective of this acquisition is to expand Advanced Enzymes capabilities of new delivery systems of our products and offering to the customers. We plan to use this new system in all three existing areas of nutraceutical, animal feed, and baking.”

“SciTech Specialities is into making effervescent tablets and these tablets we think we can take it all with all the three-segment into the B2C area that was the objective of acquiring SciTech.”

On margins, Kabra said, “At present, if you look at it for the first six months EBIT margin for SciTech is 21 percent and the PAT is about 16. 2 percent. We feel that with new products we can improve the margins of SciTech as well as we can keep our margins.”

Watch this video for more.

(Edited by : Bivekananda Biswas)

First Published:Jan 18, 2021 4:00 PM IST